Paul Weinberg, MD
Critical Care Medicine · Lawrenceville, GANPI 1447235387
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 312 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,800 and has fallen 61.2% since, to $699 in 2024. Among critical care medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 312 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- GSK$979
- AstraZeneca$846
- Insmed, Inc.$715
- Grifols USA, LLC$407
- United Therapeutics Corporation$232
- plus $2K from 29 others
Across 141 payments — averaging $3174.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$169K
- GSK$109K
- Sanofi US Services Inc.$80K
- Insmed, Inc.$53K
- Teva Pharmaceuticals USA, Inc.$24K
- Chiesi USA, Inc.$12K
What the payments were for
- Food & beverage$5,64096%
- Education$2594%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 47 | $1,074 |
| GSK | 64 | $979 |
| AstraZeneca | 46 | $846 |
| Insmed, Inc. | 31 | $715 |
| Grifols USA, LLC | 24 | $407 |
| United Therapeutics Corporation | 9 | $232 |
| Genentech USA, Inc. | 6 | $177 |
| Sanofi | 9 | $171 |
| Novartis | 7 | $124 |
| Regeneron Healthcare Solutions, Inc. | 5 | $119 |
| Mylan Specialty L.p. | 6 | $115 |
| Pfizer | 7 | $114 |
| Actelion Pharmaceuticals US, Inc. | 5 | $84 |
| Sunovion Pharmaceuticals Inc. | 5 | $59 |
| Shire North American Group Inc | 3 | $58 |
| Amgen | 4 | $55 |
| Electromed, Inc. | 3 | $50 |
| Baxter Healthcare | 3 | $48 |
| Resmed Corp | 3 | $44 |
| AbbVie | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Johnson & Johnson | 2 | $31 |
| CSL Behring | 2 | $31 |
| Advanced Respiratory, Inc | 2 | $30 |
| Philips North America LLC | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Portola Pharmaceuticals, LLC | 1 | $22 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$103
How this compares
$5,899 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 68 | $873,566 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 272 | $216,698 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $201,815 |
| Pirfenidone | 69 | $178,568 |
| Breo ElliptaFluticasone/Vilanterol | 283 | $138,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 150 | $117,729 |
| EliquisApixaban | 114 | $76,053 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 98 | $67,242 |
| Spiriva RespimatTiotropium Bromide | 77 | $55,859 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 105 | $55,661 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 24 | $50,493 |
| XareltoRivaroxaban | 36 | $42,896 |
| SymbicortBudesonide/Formoterol Fumarate | 155 | $42,465 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 77 | $11,930 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 27 | $10,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,074 | $1,004,544260 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $979 | $417,139685 claims |
| Grifols USA, LLCProlastin C | $407 | $201,81513 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $846 | $171,043332 claims |
| PfizerEliquis | $114 | $76,053114 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $17 | $50,49324 claims |
| Johnson & JohnsonXarelto | $31 | $42,89636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Lawrenceville
- Rajesh JasaniLawrenceville$8K
- Lawrence KaplanLawrenceville$4K
- Sarah HayatLawrenceville$3K
- William McGannLawrenceville$3K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.